Related Experiment Video
Updated: Dec 23, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
CREDENCE: Significant Victory for Diabetic Kidney Disease
Ashish Verma1, Ankit B Patel1, Ashish Upadhyay2
1Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Abstract:
Diabetic kidney disease (DKD), the most common cause of end-stage kidney disease (ESKD), has significant morbidity and mortality, particularly from cardiovascular complications. The CREDENCE (canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) trial reported by Perkovic and collaborators has led to an emergence of a new class of therapeutic agents for slowing DKD progression.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Kidney Transplant I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Kidney Transplant III: Nursing Management

